Department of Epidemiology and Public Health, The University of Maryland School of Medicine, Baltimore, Maryland.
Department of Pathology, The University of Maryland School of Medicine, Baltimore, Maryland.
Infect Control Hosp Epidemiol. 2023 Aug;44(8):1325-1333. doi: 10.1017/ice.2022.232. Epub 2022 Oct 3.
Hospital readmission is unsettling to patients and caregivers, costly to the healthcare system, and may leave patients at additional risk for hospital-acquired infections and other complications. We evaluated the association between comorbidities present during index coronavirus disease 2019 (COVID-19) hospitalization and the risk of 30-day readmission.
DESIGN, SETTING, AND PARTICIPANTS: We used the Premier Healthcare database to perform a retrospective cohort study of COVID-19 hospitalized patients discharged between April 2020 and March 2021 who were followed for 30 days after discharge to capture readmission to the same hospital.
Among the 331,136 unique patients in the index cohort, 36,827 (11.1%) had at least 1 all-cause readmission within 30 days. Of the readmitted patients, 11,382 (3.4%) were readmitted with COVID-19 as the primary diagnosis. In the multivariable model adjusted for demographics, hospital characteristics, coexisting comorbidities, and COVID-19 severity, each additional comorbidity category was associated with an 18% increase in the odds of all-cause readmission (adjusted odds ratio [aOR], 1.18; 95% confidence interval [CI], 1.17-1.19) and a 10% increase in the odds of readmission with COVID-19 as the primary readmission diagnosis (aOR, 1.10; 95% CI, 1.09-1.11). Lymphoma (aOR, 1.86; 95% CI, 1.58-2.19), renal failure (aOR, 1.32; 95% CI, 1.25-1.40), and chronic lung disease (aOR, 1.29; 95% CI, 1.24-1.34) were most associated with readmission for COVID-19.
Readmission within 30 days was common among COVID-19 survivors. A better understanding of comorbidities associated with readmission will aid hospital care teams in improving postdischarge care. Additionally, it will assist hospital epidemiologists and quality administrators in planning resources, allocating staff, and managing bed-flow issues to improve patient care and safety.
患者及其护理人员对住院后再次入院感到不安,这给医疗保健系统带来了沉重的负担,而且患者再次入院后可能会面临医院获得性感染和其他并发症的风险增加。我们评估了在新冠肺炎(COVID-19)住院期间存在的合并症与 30 天内再次入院风险之间的关系。
设计、地点和参与者:我们使用 Premier Healthcare 数据库对 2020 年 4 月至 2021 年 3 月期间出院的 COVID-19 住院患者进行了回顾性队列研究,这些患者在出院后 30 天内被跟踪,以记录是否再次入住同一家医院。
在指数队列的 331136 名独特患者中,有 36827 名(11.1%)在 30 天内至少有 1 次全因再次入院。在再次入院的患者中,有 11382 名(3.4%)因 COVID-19 作为主要诊断再次入院。在调整人口统计学、医院特征、并存合并症和 COVID-19 严重程度的多变量模型中,每增加一个合并症类别,全因再次入院的几率增加 18%(调整后的优势比[aOR],1.18;95%置信区间[CI],1.17-1.19),因 COVID-19 作为主要再入院诊断的几率增加 10%(aOR,1.10;95%CI,1.09-1.11)。淋巴瘤(aOR,1.86;95%CI,1.58-2.19)、肾衰竭(aOR,1.32;95%CI,1.25-1.40)和慢性肺部疾病(aOR,1.29;95%CI,1.24-1.34)与因 COVID-19 再次入院的关联最大。
COVID-19 幸存者在 30 天内再次入院很常见。更好地了解与再入院相关的合并症将有助于医院护理团队改善出院后的护理。此外,这将有助于医院流行病学家和质量管理人员规划资源、分配人员和管理床位流动问题,以改善患者护理和安全。